Real-world usage of Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD) biomarkers in nephrology practices
Fusaro, Maria (University of Padova)
Barbuto, Simona (Alma Mater Studiorum University of Bologna)
Gallieni, Maurizio (Fatebenefratelli Hospital)
Cossettini, Althea (University of Milano)
Re Sartò, Giulia Vanessa (University of Milano)
Cosmai, Laura (Fatebenefratelli Hospital)
Cianciolo, Giuseppe (Alma Mater Studiorum University of Bologna)
Manna, Gaetano L. (Alma Mater Studiorum University of Bologna)
Nickolas, Thomas (Columbia University)
Ferrari, Serge (HUG (Ginebra, Suïssa))
Bover, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Haarhaus, Mathias (Karolinska University Hospital)
Marino, Carmela (National Research Counci (Reggio Calabria, Itàlia))
Mereu, María Cristina (Cagliari, Itàlia)
Ravera, Maura (University of Genoa and Policlinico San Martino (Gènova, Itàlia))
Plebani, Mario (University of Padua)
Zaninotto, Martina (University of Padua)
Cozzolino, Mario (University of Milan)
Bianchi, Stefano (Nephrology and Dialysis Complex Operative Unit)
Messa, Piergiorgio (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Milà, Itàlia))
Gregorini, Mariacristina (Azienda Unità Sanitaria Locale di Reggio Emilia. Instituto in tecnologie avanzate e modelli assistenziali in oncologia)
Gasperoni, Lorenzo (AUSL Romagna (Rimini, Itàlia))
Agosto, Caterina (University Hospital of Padova (Pàdua, Itàlia))
Aghi, Andrea
Tripepi, Giovani (National Research Council (Reggio Calabria, Itàlia))

Data:	2024
Resum:	Background. Chronic kidney disease mineral bone disorder (CKD-MBD) is a condition characterized by alterations of calcium, phosphate, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF-23) metabolism that in turn promote bone disorders, vascular calcifications, and increase cardiovascular (CV) risk. Nephrologists' awareness of diagnostic, prognostic, and therapeutic tools to manage CKD-MBD plays a primary role in adequately preventing and managing this condition in clinical practice. Methods. A national survey (composed of 15 closed questions) was launched to inquire about the use of bone biomarkers in the management of CKD-MBD patients by nephrologists and to gain knowledge about the implementation of guideline recommendations in clinical practice. Results. One hundred and six Italian nephrologists participated in the survey for an overall response rate of about 10%. Nephrologists indicated that the laboratories of their hospitals were able to satisfy request of ionized calcium levels, 105 (99. 1%) of both PTH and alkaline phosphatase (ALP), 100 (94. 3%) of 25(OH)D, and 61 (57. 5%) of 1. 25(OH)D; while most laboratories did not support the requests of biomarkers such as FGF-23 (intact: 88. 7% and c-terminal: 93. 4%), Klotho (95. 3%; soluble form: 97. 2%), tartrate-resistant acid phosphatase 5b (TRAP-5b) (92. 5%), C-terminal telopeptide (CTX) (71. 7%), and pro-collagen type 1 N-terminal pro-peptide (P1NP) (88. 7%). As interesting data regarding Italian nephrologists' behavior to start treatment of secondary hyperparathyroidism (sHPT), the majority of clinicians used KDOQI guidelines (n = 55, 51. 9%). In contrast, only 40 nephrologists (37. 7%) relied on KDIGO guidelines, which recommended referring to values of PTH between two and nine times the upper limit of the normal range. Conclusion. Results point out a marked heterogeneity in the management of CKD-MBD by clinicians as well as a suboptimal implementation of guidelines in Italian clinical practice.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Bone biomarkers ; Bone fractures ; Bone turnover markers ; CKD-MBD ; Vascular calcifications
Publicat a:	Clinical Kidney Journal, Vol. 17 Núm. 1 (january 2024) , p. sfad290, ISSN 2048-8513

DOI: 10.1093/ckj/sfad290
PMID: 38223338

14 p, 1.7 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats